United Therapeutics
UTHR
411 hedge funds and large institutions have $6.46B invested in United Therapeutics in 2017 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 153 increasing their positions, 143 reducing their positions, and 40 closing their positions.
30% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 40
1% more funds holding
Funds holding: 406 → 411 (+5)
7% more repeat investments, than reductions
Existing positions increased: 153 | Existing positions reduced: 143
4% less call options, than puts
Call options by funds: $82.5M | Put options by funds: $85.8M
5% less capital invested
Capital invested by funds: $6.81B → $6.46B (-$347M)
5.74% less ownership
Funds ownership: 112% → 106.25% (-5.7%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$702M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$57.2M |
| 3 |
Goldman Sachs
New York
|
+$42.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.9M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$32.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$133M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$46.5M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$38.9M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$38.2M |
| 5 |
STMM
South Texas Money Management
San Antonio,
Texas
|
-$26.8M |
UTHR Hedge Fund Activity: Q1 2017 in Review
411 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2017, worth a combined $6.46B — down 5.1% from $6.81B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new UTHR positions and 40 closed out — a net gain of 12 holders — while 153 added to existing stakes and 143 trimmed.
The largest buyer was BlackRock, adding an estimated $702M. The largest seller was Scopia Capital Management, cutting an estimated $133M.
- 411 institutional investors held United Therapeutics (UTHR) as of Q1 2017, up from 406 in Q4 2016.
- Funds reported $6.46B of United Therapeutics stock for Q1 2017, down 5.1% quarter-over-quarter.
- 52 funds opened new United Therapeutics positions in Q1 2017 and 40 closed out, a net change of +12 holders.
- The largest United Therapeutics buyer in Q1 2017 was BlackRock, an estimated $702M added.
- The largest United Therapeutics seller in Q1 2017 was Scopia Capital Management, an estimated $133M sold.
Based on aggregated 13F filings for Q1 2017.